ClinicalTrials.gg
RecruitingNCT07413549HBV-DCUpdated Feb 17, 2026

Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis

A Phase 1/2 interventional study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Decompensated Hepatitis B Cirrhosis, sponsored by Beijing Tuohua Weiye Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Beijing Tuohua Weiye Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Feb 2025, registered Feb 2026).
  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 192 studies in Hepatitis B with a site in China — 39 open to participants now, 49 under way, 1 of them phase 3. Hepatitis B · China.

Planned enrollment
103rd of 136
76 · median 123
Started
2025
with 8 others
Phase 1/2
4 of 192
1 open now
Primary completion
2026-12
later than 20 of 48 live
Registered
182nd of 192
by date

Among the 192 studies in Hepatitis B with a site in China, this one is the 103rd largest by planned enrollment of the 136 interventional ones that give a count, is one of 9 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 20 of the 48 other live ones, and was the 182nd registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

39 of the 192 studies in Hepatitis B with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Hepatitis B with a site in China, or all of them as a file.
02

Study summary

Phase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis, and to determine the safe clinical dose.Secondary Objective: To evaluate the preliminary efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis, providing a basis for the design of subsequent clinical trial protocols.Exploratory Objective: To evaluate the pharmacokinetic characteristics and immunogenicity of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis.Phase II (Multiple Administrations, Randomized, Double-blind, Dose Expansion)Primary Objective: To evaluate the preliminary efficacy of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis.Secondary Objective: To evaluate the safety of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis.Exploratory Objective: To evaluate the pharmacokinetic characteristics and immunogenicity of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis.

03

Conditions studied

  • Decompensated Hepatitis B Cirrhosis

Browse trials for

Keywords

  • UC-MSCs
  • decompensated hepatitis B cirrhosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 75 years (inclusive) at screening, regardless of gender.
  • Diagnosed with decompensated cirrhosis with a history of portal hypertension-related complications according to the Guidelines for the Diagnosis and Treatment of Cirrhosis (2019 Edition).
  • After at least 3 months of strict conservative medical treatment (including antiviral therapy with nucleos(t)ide analogues, hepatoprotective, symptomatic, and nutritional support therapy), there has been no significant alleviation of cirrhosis symptoms or improvement in quality of life scores, and the investigator deems the subject suitable for stem cell therapy.
  • HBV DNA level \< 2 × 10³ IU/mL at screening.
  • Not suitable for liver transplantation, or lacking a liver donor source.
  • Both the subject and their partner have no plans for pregnancy from screening until 6 months after the end of the trial and agree to use effective non-pharmacological during the trial period.
  • Fully understand the form, voluntarily participate in the trial, and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Cirrhosis due to other causes, such as alcoholic hepatitis, virus infection, hepatitis, and metabolic dysfunction-associated steatotic liver disease (MASLD).
  • score > 12 points.
  • History of in the liver or other organs, or a family history of liver malignancy in first-degree relatives.
  • The investigator judges that the subject currently has severe internal medical diseases that would affect the safety and efficacy evaluation of the treatment, such as: cardiovascular diseases including cardiac function abnormality of Class III or above (according to criteria), ischemic heart disease (e.g., myocardial infarction or unstable angina), poorly controlled diabetes (fasting blood glucose ≥ 10 mmol/L or glycosylated () ≥ 8%), serum creatinine > 2 times the (ULN), etc.
  • Recent uncontrolled gastrointestinal bleeding (e.g., severe bleeding tendency or active bleeding within 3 months prior to screening, or major upper gastrointestinal bleeding event within 4 weeks prior to screening), deemed unsuitable for the trial by the investigator.
  • Occurrence of hepatic encephalopathy or hepatorenal syndrome within 3 months prior to screening.
  • Presence of spontaneous bacterial peritonitis or severe active infection within 2 weeks prior to screening.
  • Positive results in infectious disease serology (positive for serum anti- antibody, anti-HCV antibody, or syphilis antibody) or patients with active tuberculosis.
  • Use of human albumin within 3 weeks prior to the first infusion of the product.
  • History of venous thrombosis or pulmonary embolism, deemed unsuitable for the trial by the investigator.
  • Drug addiction or alcohol abuse.
  • Pregnant or lactating women.
  • Allergy to any component of the umbilical cord mesenchymal stem cells or , or history of severe drug allergy or allergic constitution.
  • History of severe psychiatric disorders within 24 months prior to screening, including uncontrolled severe depression or controlled/uncontrolled psychosis.
  • Participation in other interventional clinical trials within 3 months prior to screening or currently, or previous receipt of stem cell therapy.
  • Planned liver transplantation within 3 months after screening.
  • Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Human Umbilical Cord Mesenchymal Stem Cells Injection 5 × 10^7 cells per person per administration

    Duration of administration: single dose

    Biological: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stem Cells Injection 1×10^8cells per person per administration

    Duration of administration: single dose

    Biological: Human Umbilical Cord Mesenchymal Stem Cells Injection

  • Experimental
    Human Umbilical Cord Mesenchymal Stem Cells 2×10^8cells per person per administration

    Duration of administration: single dose

    Biological: Human Umbilical Cord Mesenchymal Stem Cells Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and characteristics of any adverse events and serious adverse events associated with human umbilical cord mesenchymal stem cell injection therapy

    Safety Indicator

    Time frame: within 28 days after administration

  2. Determine the recommended dose for phase II(RP2D)

    Safety Indicator

    Time frame: Periprocedural

Secondary outcomes

  1. Change of Model for End-stage Liver Disease score from baseline

    The calculated baseline score is 6 points. The 40-point mark is an upper limit set in clinical application, used to indicate an extremely high risk of mortality and to guide the most urgent allocation of liver transplants. Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  2. Child-Pugh score change from baseline

    The theoretical minimum score of the Child-Pugh classification is 5 points, and the maximum is 15 points. A higher score indicates poorer liver reserve function and a less optimistic prognosis for the patient Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  3. Hepatic hardness changes from baseline

    Efficacy Endpoint

    Time frame: Week 24, week 52 after administration

  4. Spleen hardness changes from baseline

    Efficacy Endpoint

    Time frame: Week 24, week 52 after administration

  5. Change in Liver Function Indicators from Baseline: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Bilirubin (TBIL), Gamma-Glutamyl Transferase (γ-GGT), Alkaline Phosphatase (ALP), Albumin (ALB), Cholinesterase (CHE)

    Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  6. Change in International Normalized Ratio from Baseline

    Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  7. Prothrombin Time from Baseline

    Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  8. Prothrombin Activity from Baseline

    Efficacy Endpoint

    Time frame: Week 1, week 2, week 4, week 8, week 12, week 24, week 36, week 52 after administration

  9. Change in HBV DNA from Baseline

    Efficacy Endpoint

    Time frame: Week 1, week 2, week 8, week 24, week 36, week 52 after administration

  10. Liver transplant-free survival

    Efficacy Endpoint

    Time frame: Periprocedural

  11. The incidence of complications related to decompensated cirrhosis (the following complications were calculated separately: esophageal and gastric varices bleeding, sepsis, hepatic encephalopathy, hepatorenal syndrome)

    Efficacy Endpoint and Safety Indicator

    Time frame: Periprocedural

  12. Incidence and Characteristics of Any Treatment-Related Adverse Events and Serious Adverse Events Associated with Human Umbilical Cord Mesenchymal Stem Cell Injection Therapy

    Safety Indicator

    Time frame: Week 5 to week 52 after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 17, 2026
StartActual
Feb 25, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413549
Lead sponsor
Beijing Tuohua Weiye Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 25, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Shi Cheng
Contact
thswcs@163.com
+8618504341228

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion